🇺🇸 FDA
Pipeline program

Carfilzomib

IRB00104234

Phase 1 small_molecule completed

Quick answer

Carfilzomib for Recurrent Plasma Cell Myeloma is a Phase 1 program (small_molecule) at ONCOLYTICS BIOTECH INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ONCOLYTICS BIOTECH INC
Indication
Recurrent Plasma Cell Myeloma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials